Latham & Watkins represented Coherus in the transaction. Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) has entered into a loan agreement with investment funds managed...
Coherus BioSciences’ $300 Million Credit Financing with Pharmakon Advisors
Arcutis Biotherapeutics’ $225 Million Non-Dilutive Debt Financing
Latham & Watkins represented Arcutis in the transaction. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing novel innovations in immuno-dermatology, has announced that...
UCB’s Acquisition of Zogenix
Covington represented UCB, while Latham & Watkins represented Zogenix on the deal. Fried Frank acted as counsel to BofA Securities and SVB Leerink as financial advisors to...
Medtronic’s Acquisition of Affera
Latham & Watkins represented Affer in the transaction. Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has announced that it has entered into a definitive agreement...
Royal Philips’ Acquisition of Vesper Medial
Latham & Watkins represented Vesper Medical in the transaction. Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, has signed an agreement to...
Waldencast’s $1.2 Billion Business Combination With Obagi and Milk Makeup
Skadden, Arps, Slate, Meagher & Flom represented Waldencast. Latham & Watkins, working alongside Conyers and Nixon Peabody, represented Obagi, and Goodwin Procter represented Milk Makeup in...
nThrive’s $1.7 Billion Acquisition of TransUnion Healthcare
Latham & Watkins represented TransUnion in the transaction while Sidley advised nThrive. TransUnion (NYSE: TRU) has signed a definitive agreement to sell TransUnion Healthcare, Inc. to...
Minerva Surgical’s $75 Million Initial Public Offering
Latham & Watkins represented the underwriters in the transaction. Minerva Surgical, Inc. (Minerva Surgical), a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB),...
Warby Parker’s Direct Listing
Latham & Watkins represented Warby Parker Inc. in the transaction. Warby Parker Inc. executed its direct listing on the New York Stock Exchange under the ticker symbol...
Thorne HealthTech’s $70 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati represented Thorne HealthTech, while Latham & Watkins represented the underwriters in the offering. Thorne HealthTech, a leader in developing innovative solutions...
GE Healthcare’s $1.45 Billion Acquisition of BK Medical
Schiff Hardin advised BK Medical on the deal. Latham & Watkins represented Altaris Capital. GE Healthcare has entered into an agreement to acquire BK Medical, a...
Procept BioRobotics’ $163.9 Million Initial Public Offering
Latham & Watkins represented PROCEPT in the transaction. PROCEPT BioRobotics Corporation, a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology,...